The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the ...

与此同时，欧洲麻疹疫情的急剧恶化引发了广泛关注。根据欧洲疾病预防控制中心（ECDC）公布的数据，自2024年初以来，麻疹病例在欧盟及邻国飙升至32,000多例，其中罗马尼亚成为重灾区，病例累积达到27,568例，疫情已造成至少19人死亡。紧随其后的是意大利和德国，所有国家均未能幸免。ECDC警告，麻疹疫情的传播高峰通常出现在上半年，预计未来几个月病例数可能继续增加。值得注意的是，绝大多数感染者未接 ...

当地时间3月11日，美国食品药品监督管理局（FDA）宣布批准单克隆抗体药物eculizumab用于治疗6岁及以上儿童全身型重症肌无力（gMG）。这是该群体首个靶向疗法。此前， Eculizumab已于2007年获准用于成人gMG及其他免疫性疾病。

The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...

Minneapolis, MN, March 10, 2025 (GLOBE NEWSWIRE) -- Sezzle Inc. (NASDAQ: SEZL,) (Sezzle or Company) // Purpose-driven digital payment platform, Sezzle, today announced that the Company's Board of ...

New York, March 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease that affects red blood cells, causing symptoms like dark urine, fatigue, and unexplained bruising. Early diagnosis is challenging due to ...

Five new agents to treat gMG have been approved, including three complement inhibitors -- eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq) – and two neonatal FcRn ...

Eculizumab and ravulizumab are both safe and effective and prevent relapses in patients with anti-AQP4 antibody-positive NMOSD with more than 95% of patients staying relapse-free in the follow-up ...

Importantly, none of the AEs that were observed required the use of additional immunomodulatory agents such as eculizumab, sirolimus or rituximab.